Michel Gréco

Michel Gréco graduated from the Institut d’Etudes Politiques in Paris. He holds a master's degree in Business Administration from the University of Western Ontario. He is currently active as a member of the Board of Directors of Argos Therapeutics, Inc., Immutep S.A., Vivalis S.A., Texcell S.A and Chairman of the Board of Directors of Glycovaxyn AG. He is also currently a board member of the Global Tuberculosis Vaccines Foundation, the International Aids Vaccines Initiative and the International Vaccine Institute. He is an advisor to the WHO (tuberculosis, measles). 

Up to 2003, Michel Gréco was the Deputy Chief Executive Officer and a member of the board of Aventis Pasteur S.A., now Sanofi Pasteur S.A..

He was also a member of the boards of Powderject Ltd., Flamel Technologies, Inc., ID Biomedical Corporation, DrugAbuse Sciences S.A.S.,Vaxgen Inc.and Vakzine Project Management.